Don Healey
Known title: Chief Technology OfficerCIK: 0001643067
Associated companies
Transaction History
| ACET | ▼ Sell | Tax Withholding | 535 | $5K | 1/24/2026 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 8,560 | $8K | 1/24/2025 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 4,870 | $12K | 1/24/2024 | View on chart |
| ACET | ▲ Buy | Grant | 19,700 | $0 | 1/24/2024 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 9,069 | $12K | 10/2/2023 | View on chart |
| ACET | ▼ Sell | Open Market | 4,533 | $34K | 2/15/2023 | View on chart |
| ACET | ▼ Sell | Open Market | 10,467 | $83K | 2/10/2023 | View on chart |
| ACET | ▲ Buy | Grant | 26,100 | $0 | 1/24/2023 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 7,933 | $113K | 10/4/2022 | View on chart |
| ACET | ▲ Buy | Grant | 16,000 | $0 | 8/4/2022 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 5,533 | $101K | 8/4/2022 | View on chart |
| ACET | ▲ Buy | Grant | 16,000 | $0 | 2/14/2022 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 5,533 | $79K | 2/14/2022 | View on chart |
| ACET | ▲ Buy | Grant | 16,000 | $0 | 1/28/2022 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 5,533 | $65K | 1/28/2022 | View on chart |
| ACET | ▲ Buy | Grant | 80,000 | $0 | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target
Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.
Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target. Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.